Roche to phase out microarray offering to focus on genome sequencing
This article was originally published in Clinica
Executive Summary
Roche is planning to close down or sell off its NimbleGen microarray business, according to media reports. Roche acquired NimbleGen for $272.5m in 2007 (www.clinica.co.uk, 29 June 2007); if true, the rumours could mean it is abandoning the microarray market to focus on the faster-growing next-generation genome sequencing segment.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.